Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair

Trabectedin (Yondelis(®), ecteinascidin-743, ET-743) is a marine-derived natural product approved for treatment of advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. Lurbinectedin is a novel anticancer agent structurally related to trabectedin. Both ecteinascidins generate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Michelle, Bouzid, Hana, Soares, Daniele G., Selle, Frédéric, Morel, Claire, Galmarini, Carlos M., Henriques, João A. P., Larsen, Annette K., Escargueil, Alexandre E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041952/
https://www.ncbi.nlm.nih.gov/pubmed/27029031
http://dx.doi.org/10.18632/oncotarget.8292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041952/
https://www.ncbi.nlm.nih.gov/pubmed/27029031
http://dx.doi.org/10.18632/oncotarget.8292

Ejemplares similares